Efficient production of bispecific antibody by FAST-Ig <sup>TM</sup> and its application to NXT007 for the treatment of hemophilia A-Reference-Cited by-同舟云学术

Efficient production of bispecific antibody by FAST-Ig ^TM and its application to NXT007 for the treatment of hemophilia A

Published:2023-06-20 Issue:1 Volume:15 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Koga Hikaru¹^ORCID,Yamano Takashi¹^ORCID,Betancur Juan²,Nagatomo Satoko³,Ikeda Yousuke³,Yamaguchi Kazuki¹,Nabuchi Yoshiaki¹,Sato Kazuki¹,Teranishi-Ikawa Yuri¹^ORCID,Sato Motohiko¹,Hirayama Hiroyuki¹,Hayasaka Akira¹,Torizawa Takuya¹^ORCID,Haraya Kenta¹^ORCID,Sampei Zenjiro¹^ORCID,Shiraiwa Hirotake¹,Kitazawa Takehisa¹,Igawa Tomoyuki⁴^ORCID,Kuramochi Taichi¹^ORCID

Affiliation:

1. Research Division, Chugai Pharmaceutical Co., Ltd, Yokohama, Kanagawa, Japan

2. API Process Development Department, Chugai Pharmaceutical Co., Ltd, Ukima, Tokyo, Japan

3. Analytical Development Department, Chugai Pharmaceutical Co, Ltd, Ukima, Tokyo, Japan

4. Translational Research Division, Chugai Pharmaceutical Co., Ltd, Chuo-Ku, Tokyo, Japan

Funder

supported by Chugai Pharmaceutical Co., Ltd. Funding to pay the Open Access publication charges for this article was provided by Chugai Pharmaceutical Co., Ltd

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2023.2222441

Reference65 articles.

1. Bispecific antibodies: a mechanistic review of the pipeline

2. T cell-engaging therapies — BiTEs and beyond

3. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

4. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

5. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Joint health and pain in the changing hemophilia treatment landscape;Expert Review of Hematology;2024-07-15

2. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders;Research and Practice in Thrombosis and Haemostasis;2024-05

3. Hemophilia A treatment innovation: factor VIII mimetic bispecific antibodies—generational enhancement;Journal of Thrombosis and Haemostasis;2024-02

4. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state;Journal of Thrombosis and Haemostasis;2024-02

5. Design and engineering of bispecific antibodies: insights and practical considerations;Frontiers in Bioengineering and Biotechnology;2024-01-25